Objective: To assess differential effect of statin therapy on risk of Alzheimer disease (AD) by age, sex, and presence of apolipoprotein E (APOE) e4 allele. Background: Although our previous study showed a null association between statins and risk of AD in subjects older than 65 years, statins may protective for AD in a subgroup of people who received statin therapy at relatively younger ages and carried the APOE-e4 allele. Methods: This is a prospective, cohort study of statin use and incident AD. A cohort of 2356, cognitively intact persons, aged 65 and older, were randomly selected from a large health maintenance organization, and were assessed biennially for dementia. Statin users were defined as those who received at least 3 prescriptions of a statin before onset of dementia by using the computerized pharmacy database. The potential effect modifiers included age-at-entry to study (65 to 79 vs Z80 y), sex, presence/absence of the APOE e4 allele, and preexisting of medical conditions. A proportional hazards model with statin use as a timedependent covariate was used to assess the statin-AD association. Results: Among 380 participants with incident dementia during four biennial follow-ups, 204 had probable AD. The hazard ratio for AD associated with statin use was 0.41 (95% CI 0.20-0.82) in the younger group and 1.96 (0.89 to 4.33) in the older group after adjusting for sex, education, baseline cognitive function, and other vascular risk factors. The interaction of age with statin was significant (P = 0.05). Within the younger group, the adjusted hazard ratio with statin use was 0.19 (0.05 to 0.67) for males, and 0.73 (0.31 to 1.70) for females; 0.25 (0.09 to 0.73) in those with the APOE e4 allele, and was 0.72 (0.28 to 1.85) in those without the APOE e4 allele. The interaction of statin with either sex or APOE e4 did not reach statistical significance (P>0.05). Conclusion: Our findings are consistent with the idea that statin therapy is more likely to be protective for AD when given earlier (before age 80) and modifying effect of sex and APOE e4 allele needs to be further studied. Supported in part by grants AG20020, AG06781, AG16976, and AG05136 from the National Institute of Aging, National Institutes of Health. Disclosure: The authors report no conflicts of interest.
Measures of Adiposity and Dementia Risk in the Elderly
Jose A. Luchsinger, MD, MPH*wzy, Bindu Patel, MPH*, Ming-Xin Tang, PhD*J, Nicole Shupf, PhD*wy, and Richard Mayeux, MD*wzy#. *Taub Institute for Research on Alzheimer's Disease and the Aging Brain; w Gertrude H. Sergievsky Center; Departments of JBiostatistics; yEpidemiology, Joseph P. Mailman School of Public Health, Columbia University; zDivision of General Medicine, Department of Medicine; Departments of zNeurology; and #Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY. Objective: To explore the associations of body mass index (BMI) waist circumference (WC), and weight change to dementia, probable Alzheimer disease (AD), and dementia associated with stroke (DAS) in the elderly, and its modification by age. Background: Studies of the relation between adiposity and dementia are conflicting. The association between BMI and adverse outcomes is attenuated with aging, and this may explain conflicts in the existing literature. Other measures such as WC may be better markers of adiposity in the elderly. Methods: Persons without dementia were followed for 5 years; 893 persons had BMI, 907 persons had WC, and 709 persons had a second weight measurement. Dementia was ascertained using standard methods. Cox regression was used for analyses using followup as time-to-event, adjusting for demographics, and apolipoprotein E-e4. Results: Compared with persons in the first quartile of BMI, persons in the third quartile had a lower dementia and AD risk, and persons in the second quartile had a lower DAS risk. The association between BMI and dementia resembled a U-shape in those <76 years ( Fig. 1) , whereas dementia risk decreased with higher BMI in those Z76 years. The fourth quartile of WC was related to a higher DAS risk in the whole sample, and to dementia and AD in persons <76 years (Fig. 2) . Weight loss was related to a higher dementia and DAS risk, and weight gain was related to a higher DAS risk only. Conclusions: The prospective association between adiposity and dementia differs depending on the anthropometric measure used and is modified by age. This may explain previous conflicting reports. High adiposity, ascertained by high BMI and WC, may be a risk factor for dementia, but low BMI and weight loss associated with older age and preclinical dementia may mask this association in the elderly. 
